How does the Section 174 R&D amortization requirement affect business taxes?

Beginning in 2022, IRC Section 174 requires businesses to capitalize and amortize research and experimental expenditures over five years (fifteen years for foreign research) rather than deducting them immediately. This significantly increases taxable income in the year expenses are incurred, creating substantial cash flow impacts.

Has Congress fixed the Section 174 R&D expense amortization requirement?

Despite broad bipartisan support for restoring immediate expensing of R&D costs, Congress has not enacted a fix. Several legislative proposals have been introduced but none has passed, leaving businesses to deal with the cash flow consequences of mandatory five-year amortization of research expenditures.

Research and Development Expense Amortization: The Section 174 Problem | Lynch Law

One of the most consequential—and widely criticized—provisions of the Tax Cuts and Jobs Act has now taken effect, and its impact on businesses that invest in research and development is significant. Beginning with tax years starting after December 31, 2021, IRC § 174 as amended by TCJA § 13206 requires taxpayers to capitalize and amortize research and experimental expenditures over a five-year period (fifteen years for research conducted outside the United States), rather than deducting them in the year incurred. Despite broad bipartisan support for reversing this change, Congress has not yet enacted a fix, leaving businesses to deal with the cash flow consequences of a provision that virtually everyone agrees was bad policy.^[1]

What Changed

Prior to 2022, taxpayers had the option under § 174 to deduct research and experimental expenditures in the year they were paid or incurred. This immediate deduction had been available since 1954 and was a cornerstone of the tax incentive for innovation. The TCJA amended § 174 to eliminate the immediate deduction option and instead require capitalization and amortization over five years using the midyear convention. The change was included as a revenue offset to help pay for the TCJA's other provisions, with the understanding that it would be "fixed" before it took effect. That fix has not materialized.

The scope of expenses subject to the new amortization requirement is broader than many taxpayers initially anticipated. The IRS has taken the position, consistent with the statutory language, that "specified research or experimental expenditures" include not only traditional laboratory research but also software development costs, which were previously deductible under Rev. Proc. 2000-50. For technology companies, software developers, and any business that incurs significant development costs, this expansion significantly increases the tax impact of the § 174 change.^[2]

Cash Flow Impact

The practical effect of the amortization requirement is that businesses must pay tax on income that, in economic terms, they have not yet earned. Consider a technology company that spends $1 million on software development in 2023. Under the prior rules, the full $1 million would be deductible in 2023, reducing taxable income by $1 million. Under the new rules, only $100,000 is deductible in 2023 (one-tenth of $1 million, using the midyear convention for the first year of a five-year amortization). The remaining $900,000 of deduction is spread over subsequent years. At a 21 percent corporate rate, the deferred deduction costs the company $189,000 in additional tax in the first year.

For businesses that invest heavily in R&D, the aggregate effect can be staggering. A company with $10 million in annual R&D spending could face nearly $2 million in additional tax in the first year of the amortization requirement, with diminishing but still significant impacts in subsequent years as amortization deductions from prior years begin to accumulate. For pass-through entities—including S corporations and partnerships—the impact flows through to the owners' individual returns, creating unexpected tax liabilities that may exceed the owners' available cash.

Legislative Status

The bipartisan consensus for restoring immediate R&D expensing is well-documented. Multiple legislative proposals have been introduced in both the House and Senate to repeal the amortization requirement retroactively to 2022, including the American Innovation and Jobs Act and provisions in the Tax Relief for American Families and Workers Act. As of the date of this writing, none of these proposals has been enacted into law, largely because they have been bundled with other tax provisions that do not enjoy the same level of bipartisan support.^[3]

The legislative uncertainty creates a planning dilemma for businesses. If Congress ultimately enacts a retroactive fix, businesses that capitalized and amortized their 2022 and 2023 R&D expenses will be able to claim refunds for the excess tax paid. But there is no guarantee that a fix will be enacted, or that any fix will be retroactive. Businesses must comply with the current law while monitoring legislative developments and being prepared to adjust their positions if the law changes.

Planning Considerations

In the current environment, businesses should take several steps. First, work with tax advisors to accurately identify and categorize all expenditures that fall within the scope of § 174. The broader interpretation of "specified research or experimental expenditures" means that costs previously deducted under other provisions—including software development costs—may now be subject to amortization. Proper categorization is essential to ensure compliance and to position the business to claim refunds if a retroactive fix is enacted.

Second, consider whether the R&D tax credit under § 41 can help offset the cash flow impact. The § 41 credit remains available and is calculated based on qualified research expenses, which overlap substantially with § 174 expenditures. For businesses that have not previously claimed the R&D credit, the current environment may make it worthwhile to evaluate eligibility. The credit provides a dollar-for-dollar reduction in tax liability and is available to both C corporations and pass-through entities.^[4]

Third, review estimated tax payments and cash flow projections to account for the increased tax burden resulting from the amortization requirement. Businesses that based their 2023 estimated payments on prior-year expensing methods may find themselves underpaid, potentially triggering estimated tax penalties. Adjusting estimates now can avoid penalties and improve cash flow predictability.

The § 174 amortization requirement is a significant and unwelcome change for innovative businesses. While the legislative environment suggests that a fix is more likely than not, the timing remains uncertain. Businesses that plan proactively—by accurately categorizing expenses, claiming available credits, and adjusting cash flow projections—will be best positioned to manage the impact regardless of the legislative outcome.

References

^[1] Tax Cuts and Jobs Act of 2017, Pub. L. No. 115-97, § 13206 (amending IRC § 174 to require capitalization and amortization of research expenditures for tax years beginning after Dec. 31, 2021).
^[2] IRC § 174(c)(3) (definition of specified research or experimental expenditures); the IRS has confirmed that software development costs previously deductible under Rev. Proc. 2000-50 are subject to § 174 amortization. See Notice 2023-63.
^[3] See H.R. 7024, Tax Relief for American Families and Workers Act of 2024 (passed House Jan. 2024, pending in Senate); S. 866, American Innovation and Jobs Act (introduced 2023).
^[4] IRC § 41 (credit for increasing research activities); the credit is calculated as a percentage of qualified research expenses in excess of a base amount.